H2020Индивидуална стипендия2016–2018

GallBiome · Characterization of the Human Gallbladder Microbiome

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2016-05-01 → 2018-06-30
Финансиране от ЕС
187 866 €
Участници
1
Схема
MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Микробиомът на жлъчния въдух и промените в бактериите в червата след премахването му се анализират в проекта. Това помага да се разберат причините за хроничните стомашно-чревни проблеми, които засягат значителен брой пациенти след операцията.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Characterization of the Human Gallbladder Microbiome

Cholecystitis, or inflammation of the gallbladder, occurs due to gallstone production or blockages in the cystic ducts and causes severe pain (biliary colic) and fever, often requiring surgery. When bile flow is interrupted, a number of secondary problems such as fat-soluble vitamin malabsorption and liver damage can occur. Once the gallbladder is surgically removed, patients often encounter complications in the form of acute infections or chronic bowel difficulties that can last months or years, making gallbladder disease one of the most common and costly of all digestive diseases. Post-cholecystectomy Syndrome (PCS) arises from alterations in bile flow due to loss of the reservoir function of the gallbladder, and affects approximately 20-40% of patients. Although the exact reasons have not yet been elucidated, these complications are examples of a much wider problem – unknown effects of gallbladder removal on the human body’s biggest organ, its microbiome. Without the gallbladder, the body lacks a way of regulating the flow of bile into the intestines. It is expected that the increased bile flow leads to downstream changes in the intestinal population, but no such studies have been performed in humans. Cholecystectomies rank number one for the most frequently performed major surgery. The National Health and Nutrition Examination Survey in the US estimated that 6.3 million men and 14.2 million women aged 20-74 yrs suffer gallbladder disease. The prevalence is 20 million cases among Europeans, whereby the incidence of gallstones is 1 million new cases/yr. In the US, direct and indirect costs of gallbladder disease represented a consumption of $6.2 billion in 2012, increasing by more than 20% over the last three decades. In 2013 England reported >12,000 cases of cholelithiasis, making it one of the primary reasons for hospital visits relating to gastrointestinal issues. Treatment is governed by non-specific diagnoses and usually includes pharmacologic or surgical approaches. As these number increase, considerable burden is placed on the healthcare system and taxpayer funds. However, the degree of research in this topic does not reflect demand, and much remains to be known about the epidemiology of gallbladder disease. The MSCA-funded GallBiome project aimed to define the core gallbladder microbiome. It was hypothesized that measurable differences would be seen among the dominant phyla in healthy compared to diseased gallbladders and that removal of the gallbladder would lead to gut dysbiosis. To investigate these questions the fellow sought to achieve the following objectives: 1) mapping community changes linked to gallbladder disease; 2) quantifying changes in bacterial communities from gallbladder mucosa, bile, and stool as a function of time and patient status, 3) evaluations of gallbladder removal on the gut population (3) correlations among population profiles with metabolite profiles to glean microbial functions, and 4) the isolation and characterization of previously uncultivated anaerobic bacteria. Ultimately, this project seeks to understand the role of bacteria in gallbladder disease and will form the basis for establishing relationships between gallbladder microbiota and gut microbiota to benefit human health.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The human gastrointestinal tract harbors a complex community of microorganisms that confer metabolic, immunological and neurological benefits to the host. This assemblage is known as the Gut Microbiome and has received increased attention over the last decade. Scientists have begun to uncover the importance of these bacterial inhabitants and expand investigations to consider how site-specific microbiomes affect host physiology. While more than one million cholecystectomies (gallbladder removal surgeries) are performed throughout Europe each year, the bacterial communities associated with the human gallbladder and its disease states remain unknown. Studies are lacking that characterize the effects of cholecystectomies on the gut microbiome. Without the ability to regulate bile entering the duodenum during food intake, it is expected that gallbladder removal will lead to downstream changes in the intestinal population. Here, the microbial composition of human bile, gallbladder mucosa, and biopsies of surgically removed healthy gallbladders (adherent and non-adherent microbiota) will be investigated using 16S rRNA metagenomics. The profiles will be compared to samples of a second cohort undergoing emergency cholecystectomies, in order to identify possible biomarkers for gallbladder disease. Once the gallbladder microbiome has been elucidated, the impact of its removal on the gut microbiome will be assessed. Using molecular and cultivation based techniques, on stool samples (collected during the recovery period) and analyzed for community composition, metabolomics, bile, fat and energy content. GallBiome will form the basis for establishing relationships between gallbladder microbiota, gut microbiota, and human health with a view to informing future development of diagnostics and therapeutics. Ultimately, characterization of the core gallbladder microbiome has important biological and medical implications with potential to lower the risk and incidence of cholelithiasis.

Оригинален текст от CORDIS (на английски).

Участници

  • TEAGASC - AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY · CarlowКоординаторИрландия

Връзки

Данни: CORDIS, © Европейски съюз